New scan may predict which breast cancers resist hormone therapy
NCT ID NCT04573231
First seen Jan 05, 2026 · Last updated Jun 16, 2026 · Updated 23 times
Summary
This study is looking at a protein called PSMA in a specific type of advanced breast cancer (HER2-negative, AR-positive). Researchers want to see if PSMA levels on a PET scan can predict whether the cancer will resist a hormone-blocking drug called bicalutamide. About 15 people will join, and the study involves one PET scan and lasts about 3 days. The goal is to better understand treatment resistance, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin School of Medicine and Public Health
RECRUITINGMadison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.